Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, is developing cancer treatments for genomically defined patient populations. The company's lead program is seribantumab, in a Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology was incorporated in 2019 and is based in New York, NY.
What is Elevation Oncology's quote symbol?
What is the 52 week high and low for Elevation Oncology (NASDAQ: ELEV)?
How much is Elevation Oncology stock worth today?
How much is Elevation Oncology's stock price per share?
What is Elevation Oncology's Market Cap?